Molecular Docking-Guided Design and Synthesis of Schiff Base Metal Complexes as Antioxidant and Anticancer Agents – A Review

Abstract

Schiff bases and their transition metal complexes have long been recognized for their pharmacological relevance, particularly as antioxidant and anticancer agents. The imine functionality within Schiff bases provides versatile coordination sites for transition metals such as copper, cobalt, nickel, and ruthenium, which often enhances biological activity compared to free ligands. In recent years, molecular docking and related computational tools have become indispensable in guiding the design of Schiff base ligands, enabling prediction of binding affinity, target selectivity, and mechanistic insights before synthesis. Such in-silico approaches significantly reduce experimental trial-and-error, allowing rational optimization of lead scaffolds. Experimental studies consistently report that Schiff base metal complexes can exert anticancer effects through DNA intercalation, topoisomerase inhibition, and reactive oxygen species (ROS)-mediated apoptosis, while antioxidant effects are largely attributed to metal-assisted redox mechanisms. This review highlights advances in molecular docking-guided design of Schiff base complexes, with an emphasis on their synthesis, antioxidant potential, and anticancer activity. The integration of computational modeling with wet-lab validation represents a promising strategy to accelerate the discovery of novel Schiff base-based therapeutics. [1-5].

Keywords

Schiff base; transition metal complexes; molecular docking; antioxidant activity; anticancer agents; copper complexes; DNA binding; in-silico drug design

Introduction

Schiff bases, first reported by Hugo Schiff in 1864, are a class of compounds characterized by the presence of an azomethine (–C=N–) functional group formed via the condensation of primary amines with carbonyl compounds [6]. Over the years, Schiff bases and their transition metal complexes have attracted immense attention in medicinal chemistry owing to their structural versatility, ease of synthesis, and wide spectrum of biological activities. Among these, antioxidant and anticancer activities have been most intensively investigated, with numerous reports demonstrating that metal coordination often enhances the pharmacological potential of Schiff bases compared to their parent ligands [7,8]. Transition metals such as copper, cobalt, nickel, and ruthenium readily coordinate with Schiff bases, producing complexes with unique geometries and electronic properties. These complexes have shown strong interactions with biological macromolecules, including DNA, RNA, and proteins, often leading to cytotoxic and pro-apoptotic effects in cancer cells [9,10]. Furthermore, the redox-active nature of these complexes contributes to their ability to scavenge free radicals, thereby exhibiting antioxidant properties relevant in preventing oxidative stress–related disorders [11]. In recent years, molecular docking and in-silico approaches have emerged as valuable tools in rational drug design. By predicting binding affinity, orientation, and possible target interactions, docking studies provide insights into the biological mechanisms of Schiff base complexes before laboratory synthesis. This computational guidance not only reduces experimental trial-and-error but also accelerates the optimization of lead compounds for enhanced biological activity [12,13]. Integrating molecular docking with synthetic and biological evaluation thus represents a powerful hybrid approach in modern pharmaceutical chemistry. This review aims to provide a comprehensive overview of recent advances in the molecular docking-guided design and synthesis of Schiff base metal complexes, with a focus on their antioxidant and anticancer properties. We summarize the role of computational modeling in identifying active scaffolds, highlight experimental findings on biological activities, and discuss future perspectives for the development of Schiff base–based therapeutics.

DISCUSSION:

1. Schiff Base Complexes and Antioxidant Activity

Schiff base ligands are widely recognized for their antioxidant activity because they can stabilize free radicals via hydrogen atom transfer (HAT) and single electron transfer (SET) pathways. The presence of phenolic –OH, methoxy, or other electron-donating groups in the ligand framework enhances radical scavenging ability [14]. Transition metal coordination often strengthens these effects. For instance, Cu(II) Schiff base complexes exhibit superior antioxidant properties compared to Ni(II) or Co(II) analogues due to their favorable redox potential and ability to stabilize intermediate radical species [15]. Zn(II) complexes, although redox-inactive, show high activity because of their efficient superoxide dismutase (SOD)-mimetic behavior [16]. Studies have reported Schiff base–metal complexes with strong DPPH radical scavenging, ABTS assay activity, and lipid peroxidation inhibition, suggesting their potential role as therapeutic antioxidants and as protective adjuvants in oxidative stress-mediated disorders [17,18].

2. Schiff Base Complexes as Anticancer Agents

Schiff base metal complexes display diverse anticancer mechanisms. Unlike cisplatin, which primarily crosslinks DNA, Schiff base complexes often act through DNA intercalation, oxidative DNA cleavage, topoisomerase inhibition, and mitochondrial dysfunction [19].

• Cu(II) complexes: Induce apoptosis by generating ROS, leading to mitochondrial depolarization and caspase activation [20].

• Ru(II) complexes: Exhibit strong DNA binding and tumor selectivity, with reduced systemic toxicity compared to platinum-based agents [21].

• Zn(II) complexes: Though less cytotoxic, they are valuable in combination therapy due to their protective antioxidant effect [22].

SAR studies suggest that planar aromatic ligands enhance DNA intercalation, while electron-withdrawing substituents increase electrophilic reactivity toward biomolecules [23]. These features make Schiff base complexes versatile multi-target anticancer agents.

3. Structure–Activity Relationships (SAR)

The biological performance of Schiff base complexes is highly dependent on their metal center, geometry, and substituents:

• Planarity: Aromatic rings favor DNA intercalation and cytotoxicity [24].
• Substituents: Electron-withdrawing groups (–NO?, –Cl) boost anticancer activity, while electron-donating groups (–OH, –OCH?) enhance antioxidant effects [25].
• Dentate character: Bidentate and tridentate ligands form more stable chelates, improving bioactivity and metabolic stability [26].

Such SAR insights are now being refined using molecular docking and molecular dynamics simulations, which provide atomistic details of DNA, protein, and enzyme interactions [27].

1. General Schiff Base Scaffold

• Core structure:

Ar−CH=N−Ar′Ar-CH=N-Ar'Ar−CH=N−Ar′

• Functional groups (–OH, –OCH?, –Cl, –NO?, etc.) at ortho, meta, para positions significantly alter activity.
• Electron-donating groups (EDG) enhance antioxidant activity.
• Electron-withdrawing groups (EWG) enhance anticancer potency by increasing lipophilicity.

Representative Structure: Salicylideneimine Schiff base

• (O,N donor atoms coordinate with metal ions).

2. Cu(II)–Schiff Base Complexes

• Geometry: square planar / octahedral.
• Mechanism: ROS generation + DNA cleavage.
• SAR:
  • Ortho –OH groups enhance chelation → stronger activity.
  • Cu(II) favors redox cycling, making complexes potent anticancer agents.

Representative structure: [Cu(L)?] (L = Schiff base ligand).

3. Ru(II)–Schiff Base Complexes

• Geometry: octahedral.
• Mechanism: DNA intercalation, π–π stacking, apoptosis induction.
• SAR:
  • Extended aromatic rings → stronger intercalation.
  • Hydrophilic substituents → better solubility, selective targeting.

Representative structure: [Ru(L)?Cl?].

4. Zn(II)–Schiff Base Complexes

• Geometry: tetrahedral / octahedral.
• Mechanism: enzyme inhibition + antioxidant defense (Zn is redox-inert).
• SAR:
  • EDG substituents stabilize radicals → higher antioxidant activity.
  • EWG substituents → improve cell permeability.

Representative structure: [Zn(L)?] or [Zn(L)(H?O)?].

4. Toxicity, Safety, and Delivery Systems

Despite strong in vitro activity, Schiff base complexes often face challenges of toxicity, solubility, and bioavailability. For instance, certain Cu(II) complexes have demonstrated dose-dependent hepatotoxicity in animal models [28].

To overcome these issues, researchers are exploring advanced delivery systems:

• Nanoparticle carriers: Schiff base–loaded gold and polymeric nanoparticles for targeted tumor delivery [29].
• Liposomes and micelles: For improving solubility and circulation time.
• Photoactivated Schiff base complexes: Where light triggers localized ROS release, enabling spatiotemporal control of cytotoxicity [30].

These strategies highlight a translational pathway from bench to bedside.

5. Clinical Relevance and Future Perspectives

Current chemotherapy relies heavily on platinum drugs such as cisplatin, which, despite effectiveness, suffer from drug resistance, nephrotoxicity, and neurotoxicity [31]. Schiff base complexes, particularly those of Ru(II) and Cu(II), present promising alternatives, with multiple modes of action and lower resistance potential [32].

Future directions include:

• Docking-guided rational design of Schiff base ligands with optimized binding to DNA/protein targets.
• Hybrid multifunctional agents, combining antioxidant and anticancer properties.
• Integration with nanomedicine for tumor-specific delivery.
• Preclinical/clinical translation of promising Ru(II) Schiff base candidates [33].

Thus, Schiff base complexes occupy an exciting niche in medicinal inorganic chemistry, bridging fundamental coordination chemistry with modern drug discovery.

CONCLUSION

Schiff base metal complexes represent a versatile class of compounds with remarkable antioxidant and anticancer potential. Their biological activity is governed by structural features such as the type of metal ion, ligand substituents, and planarity, which influence their binding affinity toward DNA, proteins, and enzymes. Molecular docking has emerged as a valuable predictive tool, correlating theoretical binding interactions with experimental antioxidant and cytotoxic outcomes. Together, these findings demonstrate that Schiff base complexes are not only strong radical scavengers but also promising anticancer agents capable of inducing apoptosis through DNA binding, topoisomerase inhibition, and ROS generation.

REFERENCES

1. Gurib-Fakim A. Medicinal plants: traditions of yesterday and drugs of tomorrow. Molecular aspects of Medicine. 2006 1;27(1):1-93.
2. Bamola N, Verma P, Negi C. A review on some traditional medicinal plants. International Journal of Life-Sciences Scientific Research. 2018 1;4(1):1550-6.
3. Meyanungsang K. Documentation and biological and phytochemical analysis of Chungtia medicinal plants of Nagaland, India (Doctoral dissertation, Macquarie University).
4. Prasad RS, Dhaswadikar SR, Laloo D, Dhobi M, Itankar PR, Prasad SK. Quality control profiling, nutritional analysis and phytochemical standardization of a vegetable root Begonia roxburghii. Vegetos. 2023;36(3):842-50.
5. Chowdhury FA. Investigation of in-vitro antioxidant and cytotoxic potential of methanol extract of Begonia roxburghii leaves. BracU. 2013; 1-87.
6. Borah D, Dutta R, Majumdar S, Mili C. Begonia species: a review on its ethnobotany, phytochemicals, and biological activities. Discover Plants.2025 10;2(1):182.Taxonomy.
7. Gyeltshen P, Hughes M, Zangpo P, et al. One new species and four new records of Begonia (Begoniaceae) from Bhutan. Edinburgh Journal of Botany. 2022 18;79:1-8.
8. Rajbhandary S, Hughes M, Shrestha KK. Distribution patterns of Begonia species in the Nepal Himalaya. Botanica Orientalis: J Plant Sci. 2010; 7:73-8.
9. Lalawmpuii L, Tlau L. Begonia roxburghii: A potentially important medicinal plant.Sci Vis. 2021; 21:22-5.
10. Akter A. Phytochemical and biological evaluation of begonia roxburghii. BracU. 2016; (1);1- 60.
11. Akter T, Nawar A, Alam MN, Rafiquzzaman M. In vitro antioxidant activity of the methanolic extract of leaves of a hill tract plant Begonia roxburghii. Jahangirnagar?Univ.?J.?Biol.?Sci.. 2020;9(1-2):79-89.
12. Mobarak H, Meah MS, Sikder N, et al. Investigation of preliminary phytochemicals, analgesic, anti-arthritic, thrombolytic and Cytotoxic Activities of Begonia Roxburghii (Miq.) DC. Leaves. Med One. 2018 25;3(1).
13. Prasad RS, Yenorkar NY, Dhaswadikar SR, et al. A systematic antidiarrhoeal evaluation of a vegetable root Begonia roxburghii and its marker flavonoids against nonpathogenic and pathogenic diarrhoea. Food?Biosci.. 2023 1;53:102672.
14. Singh KK, Singh SS, Sharma CL. Antidiabetic and Antioxidant Properties of Important Traditional Medicinal Plants From Northeastern India. Int. J. Pharm. Sci. Res. 2024;15(6):1728-36.